Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
Moroxybrate, a drug obtained by the reaction of clofibric acid with moroxydine, a biguanide with practically no effect on carbohydrate metabolism, has been examined for its effects on blood lipids, fibrinogen, in-vitro platelet aggregation, and also on experimental atherosclerotic lesions obtained by feeding the rabbits a diet containing 1% cholesterol. At the same dose, moroxybrate has an effect at least equal to those of clofibrate and moroxydine alone, on the lipidic parameters and haemostasis in rat and rabbit. The combination of these actions together with an effect on the prevention of experimental atherosclerosis lesions in the rabbit suggests moroxybrate should be examined for its effects in ischaemic cardiovascular disease.
D000818:Animals; D000925:Anticoagulants; D001161:Arteriosclerosis / Q000517:prevention & control*; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D004041:Dietary Fats / Q000008:administration & dosage; D005343:Fibrinolytic Agents; D000960:Hypolipidemic Agents; D008055:Lipids / Q000097:blood; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains
D000925:Anticoagulants; D004041:Dietary Fats; D005343:Fibrinolytic Agents; D000960:Hypolipidemic Agents; D008055:Lipids; D009025:Morpholines; D002995:Clofibric Acid; C051824:moroxybrate; D002994:Clofibrate